ERYTECH Pharma S.A.
Develops red blood cell-based therapies for cancer and orphan diseases.
ERYP | PA
Overview
Corporate Details
- ISIN(s):
- FR0010417360 (+2 more)
- LEI:
- 969500U8ZZCODU8A9374
- Country:
- France
- Address:
- 60 AVENUE ROCKEFELLER, 69008 LYON
- Website:
- https://phaxiam.com/
- Sector:
- Manufacturing
Description
ERYTECH Pharma S.A. is a clinical-stage biopharmaceutical company that develops innovative therapeutics based on its proprietary ERYCAPS platform, which encapsulates drug substances inside red blood cells. This technology is designed to improve the efficacy and safety of treatments by prolonging the drug's circulation time and reducing side effects. The company's primary focus is on developing treatments for severe forms of cancer and orphan diseases. Its lead product candidate, eryaspase, encapsulates the enzyme L-asparaginase to starve cancer cells of essential nutrients, targeting indications such as acute lymphoblastic leukemia and pancreatic cancer.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-07-04 15:06 |
Franchissement de seuils et déclaration d'intention
|
French | 285.0 KB | ||
| 2024-07-03 18:00 |
Information mensuelle relative au nombre total de droits de vote et d’actions c…
|
French | 175.0 KB | ||
| 2024-07-03 18:00 |
Monthly information related to total number of voting rights and shares composi…
|
English | 158.3 KB | ||
| 2024-06-28 17:45 |
Results of the Combined General Meeting of 28 June 2024
|
English | 209.9 KB | ||
| 2024-06-28 17:45 |
Résultats de l'Assemblée Générale Mixte du 28 juin 2024
|
French | 205.3 KB | ||
| 2024-06-27 17:45 |
PHAXIAM Therapeutics annonce le succès de son augmentation de capital avec main…
|
French | 347.8 KB | ||
| 2024-06-12 08:00 |
Lancement d'une augmentation de capital avec maintien du DPS d’un montant d’env…
|
French | 852.3 KB | ||
| 2024-06-07 17:45 |
PHAXIAM announces the availability of the preparatory documents for the Combine…
|
English | 213.7 KB | ||
| 2024-06-07 17:45 |
PHAXIAM annonce les modalités de mise à disposition des documents préparatoires…
|
French | 225.0 KB | ||
| 2024-06-05 18:00 |
Information mensuelle relative au nombre total de droits de vote et d’actions c…
|
French | 174.7 KB | ||
| 2024-06-05 18:00 |
Monthly information related to total number of voting rights and shares composi…
|
English | 157.9 KB | ||
| 2024-05-15 17:45 |
PHAXIAM provides Business and Financial Update for the First Quarter of 2024
|
English | 219.9 KB | ||
| 2024-05-15 17:45 |
PHAXIAM Therapeutics fait le point sur ses activités et publie l’information fi…
|
French | 245.4 KB | ||
| 2024-05-03 18:05 |
Information mensuelle relative au nombre total de droits de vote et d’actions c…
|
French | 174.3 KB | ||
| 2024-05-03 18:05 |
Monthly information related to total number of voting rights and shares composi…
|
English | 157.7 KB |
Automate Your Workflow. Get a real-time feed of all ERYTECH Pharma S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for ERYTECH Pharma S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for ERYTECH Pharma S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-06-23 | N/A | Other | Other | 3,697,533 | 2,255,495.13 EUR |
| 2023-06-23 | N/A | Other | Other | 71,839 | 43,821.79 EUR |
| 2023-06-23 | N/A | Other | Other | 54,862 | 33,465.82 EUR |
Peer Companies
